Open AccessDupilumab (Dupixent)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.93
Subject(s) - medicine , asthma , quality of life (healthcare) , economic evaluation , corticosteroid , dupilumab , intensive care medicine , pediatrics , pathology , nursing
Clinical evidence suggests that Dupixent should be reimbursed to treat patients aged 12 years and older with severe asthma and with a type 2 or eosinophilic phenotype or oral corticosteroid–dependent asthma.
Economic evidence suggests that a 93% price reduction is needed to ensure Dupixent is cost-effective at a $50,000 per quality-adjusted life-year threshold relative to standard of care alone.
Cost-effectiveness versus other biologics is unknown.
CADTH was unable to estimate the budget impact due to a high degree of uncertainty.